How Rocklatan Combines Two Glaucoma Meds
Rocklatan is a fixed-dose combination eye drop that merges netarsudil and latanoprost to lower intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Netarsudil, a rho kinase inhibitor, increases trabecular meshwork outflow by relaxing the eye's drainage tissue and reducing fluid production. Latanoprost, a prostaglandin analog, boosts uveoscleral outflow by mimicking natural prostaglandins that open alternative drainage pathways.[1]
The two active ingredients sit in a single preservative-free formulation—one drop per day—allowing simultaneous action on multiple outflow routes for greater IOP reduction than either drug alone. Clinical trials showed Rocklatan drops IOP by up to 33% from baseline, outperforming latanoprost monotherapy by 1.3-2.4 mmHg.[2]
Why Combine Netarsudil and Latanoprost?
This pairing targets complementary mechanisms: netarsudil acts quickly on conventional outflow (70% of eye drainage), while latanoprost enhances non-conventional pathways. Alone, latanoprost reduces IOP by 25-35%; netarsudil adds 15-25% more via a novel pathway resistant to other classes. The combo avoids polypharmacy issues like adherence problems from multiple daily drops.[1][2]
Rocklatan vs. Other Glaucoma Combos
Unlike Combigan (brimonidine/timolol) or Cosopt (dorzolamide/timolol), which pair drops with beta-blockers or carbonic anhydrase inhibitors, Rocklatan skips those classes to minimize systemic side effects like heart rate changes. It rivals Vyzulta (latanoprostene bunod) but adds netarsudil's outflow boost for broader efficacy in treatment-resistant cases.[2]
| Combo | Mechanisms | Dosing | Avg. IOP Drop |
|-------|------------|--------|---------------|
| Rocklatan | Rho kinase + PG analog | 1 drop daily | 28-33% |
| Combigan | Alpha agonist + beta-blocker | 2-3 drops daily | 20-28% |
| Simbrinza | CAI + alpha agonist | 3 drops daily | 21-27% |
Common Side Effects Patients Report
Most issues are local: conjunctival hyperemia (redness) in 50-60% of users from netarsudil, plus latanoprost-linked iris darkening or eyelash growth (5-10%). Corneal deposits occur in under 20%, often resolving without stopping treatment. No major systemic risks beyond mild headaches.[2]
Who Makes Rocklatan and Patent Status?
Aerie Pharmaceuticals (now part of Alcon) developed and markets it, approved by FDA in 2019. Key patents cover the netarsudil-latanoprost formulation through 2032, with pediatric exclusivity to 2037. Check DrugPatentWatch.com for challenges or expiry details: https://www.drugpatentwatch.com/p/tradename/ROCKLATAN.[3]
[1] Rocklatan Prescribing Information, Aerie Pharmaceuticals, 2023.
[2] FDA Approval Summary and ROCKET Trials (Phase 3 data), Ophthalmology, 2019.
[3] DrugPatentWatch.com, Rocklatan patents accessed 2024.